Lord, Abbett & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $388M | Buy |
421,643
+165,887
| +65% | +$168M | 1.27% | 9 |
|
|
2025
Q4 | $275M | Buy |
255,756
+146,036
| +133% | +$140M | 0.84% | 25 |
|
|
2025
Q3 | $83.7M | Sell |
109,720
-37,718
| -26% | -$28.1M | 0.25% | 109 |
|
|
2025
Q2 | $115M | Sell |
147,438
-75,524
| -34% | -$58.7M | 0.37% | 78 |
|
|
2025
Q1 | $184M | Buy |
222,962
+78,152
| +54% | +$65M | 0.66% | 33 |
|
|
2024
Q4 | $112M | Sell |
144,810
-233,200
| -62% | -$193M | 0.35% | 81 |
|
|
2024
Q3 | $335M | Sell |
378,010
-71,978
| -16% | -$64.7M | 1.07% | 13 |
|
|
2024
Q2 | $407M | Buy |
449,988
+34,925
| +8% | +$27.9M | 1.33% | 7 |
|
|
2024
Q1 | $323M | Sell |
415,063
-38,005
| -8% | -$27M | 1.04% | 9 |
|
|
2023
Q4 | $264M | Sell |
453,068
-151,837
| -25% | -$88.6M | 0.93% | 12 |
|
|
2023
Q3 | $325M | Sell |
604,905
-21,786
| -3% | -$11.2M | 1.21% | 7 |
|
|
2023
Q2 | $294M | Buy |
626,691
+192,241
| +44% | +$80.6M | 1.01% | 7 |
|
|
2023
Q1 | $149M | Sell |
434,450
-439,002
| -50% | -$148M | 0.54% | 33 |
|
|
2022
Q4 | $320M | Sell |
873,452
-110,648
| -11% | -$39.2M | 1.14% | 10 |
|
|
2022
Q3 | $318M | Buy |
984,100
+253,940
| +35% | +$80.5M | 1.16% | 8 |
|
|
2022
Q2 | $237M | Buy |
730,160
+218,147
| +43% | +$65.5M | 0.84% | 15 |
|
|
2022
Q1 | $147M | Sell |
512,013
-133,166
| -21% | -$34.3M | 0.39% | 60 |
|
|
2021
Q4 | $178M | Sell |
645,179
-6,313
| -1% | -$1.6M | 0.41% | 59 |
|
|
2021
Q3 | $151M | Buy |
651,492
+20,592
| +3% | +$5.08M | 0.36% | 73 |
|
|
2021
Q2 | $145M | Sell |
630,900
-147,305
| -19% | -$29.6M | 0.35% | 76 |
|
|
2021
Q1 | $145M | Buy |
778,205
+231,403
| +42% | +$45.3M | 0.37% | 63 |
|
|
2020
Q4 | $92.3M | Buy |
+546,802
| New | +$81.6M | 0.24% | 124 |
|
|
2019
Q1 | – | Sell |
-181,263
| Closed | -$21M | – | 754 |
|
|
2018
Q4 | $21M | Sell |
181,263
-30,363
| -14% | -$3.39M | 0.08% | 374 |
|
|
2018
Q3 | $22.7M | Buy |
+211,626
| New | +$21.2M | 0.06% | 446 |
|
|
2016
Q2 | – | Sell |
-396,617
| Closed | -$28.6M | – | 901 |
|
|
2016
Q1 | $28.6M | Sell |
396,617
-1,317,533
| -77% | -$99.7M | 0.09% | 335 |
|
|
2015
Q4 | $144M | Sell |
1,714,150
-883,382
| -34% | -$73.3M | 0.43% | 34 |
|
|
2015
Q3 | $217M | Sell |
2,597,532
-2,141,164
| -45% | -$181M | 0.66% | 14 |
|
|
2015
Q2 | $396M | Sell |
4,738,696
-1,242,674
| -21% | -$94.7M | 1.04% | 4 |
|
|
2015
Q1 | $435M | Buy |
5,981,370
+616,864
| +11% | +$43.9M | 1.1% | 4 |
|
|
2014
Q4 | $370M | Sell |
5,364,506
-668,020
| -11% | -$45.1M | 0.94% | 7 |
|
|
2014
Q3 | $391M | Buy |
6,032,526
+3,726,265
| +162% | +$236M | 0.98% | 6 |
|
|
2014
Q2 | $143M | Sell |
2,306,261
-591,981
| -20% | -$35.3M | 0.33% | 81 |
|
|
2014
Q1 | $171M | Sell |
2,898,242
-76,379
| -3% | -$4.26M | 0.39% | 55 |
|
|
2013
Q4 | $152M | Sell |
2,974,621
-2,642,052
| -47% | -$132M | 0.34% | 63 |
|
|
2013
Q3 | $283M | Buy |
5,616,673
+2,181,297
| +63% | +$114M | 0.65% | 16 |
|
|
2013
Q2 | $169M | Buy |
+3,435,376
| New | +$187M | 0.39% | 49 |
|
Other funds holding LLY
VCM
VPM
Lord, Abbett & Co's LLY Position: Q1 2026 in Review
Lord, Abbett & Co increased its Eli Lilly (LLY) stake by 65% in Q1 2026, buying an estimated $168M and bringing the position to 421,643 shares worth $388M. The position accounts for 1.27% of the portfolio, ranked #9.
Lord, Abbett & Co first reported a position in LLY in Q2 2013 and has held it in 36 quarters since. The position peaked at $435M in Q1 2015. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Lord, Abbett & Co held 421,643 shares of Eli Lilly worth $388M as of Q1 2026.
- Lord, Abbett & Co bought 165,887 Eli Lilly shares in Q1 2026, an estimated $168M.
- Eli Lilly made up 1.27% of Lord, Abbett & Co's portfolio in Q1 2026, its #9 holding.
- Lord, Abbett & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 36 quarters since.
- Lord, Abbett & Co's Eli Lilly position peaked at $435M in Q1 2015.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.